LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Strona główna・Stock List・Puma Biotechnology Inc

Puma Biotechnology Inc

Closed

SectorHealthcare

5.61 0.18

Buy Sell

Overview

Share price change

24h

Current

Min

5.54

Max

5.64

Key metrics
By Trading Economics
Income	3M 8.8M
Sales	2M 54M
P/E Sector Avg	7.865 76.798
EPS	0.21
Profit margin	16.235
Employees	172
EBITDA	2.7M 13M

Recommendations
By TipRanks
Recommendations	Sell
12 Months Forecast	-37.83% downside

Market Stats
By TradingEconomics
Market Cap	39M 293M
Previous open	5.43
Previous close	5.61

News Sentiment

By Acuity

31%

69%

70 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

3.07 / 3.075 Support & Resistance

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 gru 2025, 17:29 UTC

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19 gru 2025, 16:47 UTC

Major Market Movers

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19 gru 2025, 16:10 UTC

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

20 gru 2025, 19:00 UTC

Earnings

Consumer Confidence, Economic Activity Data, and a Short Trading Week for Christmas -- Barrons.com

19 gru 2025, 22:33 UTC

Earnings

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19 gru 2025, 22:19 UTC

Earnings

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19 gru 2025, 21:48 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 21:44 UTC

Earnings

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 gru 2025, 21:38 UTC

Earnings

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19 gru 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19 gru 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19 gru 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19 gru 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19 gru 2025, 18:00 UTC

Market Talk

Earnings

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19 gru 2025, 17:41 UTC

Earnings

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 gru 2025, 17:24 UTC

Market Talk

Earnings

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19 gru 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

19 gru 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19 gru 2025, 16:29 UTC

Earnings

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19 gru 2025, 16:20 UTC

Acquisitions, Mergers, Takeovers

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19 gru 2025, 16:19 UTC

Acquisitions, Mergers, Takeovers

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19 gru 2025, 16:18 UTC

Acquisitions, Mergers, Takeovers

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19 gru 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 gru 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19 gru 2025, 16:05 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 16:04 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19 gru 2025, 15:21 UTC

Market Talk

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19 gru 2025, 15:09 UTC

Market Talk

Gold Flat But Set for Weekly Gains -- Market Talk

19 gru 2025, 15:09 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-37.83% downside

12 Months Forecast

Average 3.5 USD -37.83%

High 5 USD

Low 2 USD

Based on 2 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Puma Biotechnology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

70 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.